drugset / Trial / NCT00463151
An Exploratory Study of Rebamipide in Patients With Active Ulcerative Colitis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to examine the safety and efficacy of rebamipide by once daily intracolonial administration at 0 (placebo), 60, 150, or 300 mg for 6 weeks in patients with active ulcerative colitis, who are being treated with oral aminosalicylic acid (ASA).
Timeline
- Start
- 2007-06
- Primary completion
- 2008-08
- Completion
- 2008-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rebamipide | Small molecule | 60 mg | Other |
| Subject | Rebamipide | Small molecule | 150 mg | Other |
| Subject | Rebamipide | Small molecule | 300 mg | Other |